Efficacy and safety of renal denervation in resistant hypertension: two years follow-up
DOI:
https://doi.org/10.52692/1857-0011.2023.1-75.08Keywords:
renal denervation, resistant hypertensionAbstract
Hypertension remains a major cause of cardiovascular morbidity and mortality globally. Difficulties faced by clinicians to obtain adequate blood pressure control in patients with resistant hypertension have led to the development of alternative device-based treatment methods, one of which is renal artery denervation.In the current paper, the results of the study carried out in the Hypertension Department of the Institute of Cardiology regarding the evaluation of the effectiveness and safety of renal artery denervation in patients with resistant HTN two years post-procedural are presented.
References
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020; 396:1223-49.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 2021; 398:957-80.
Ettehad D., Emdin C.A., Kiran A., Anderson S.G., Callender T., Emberson J., Chalmers J., Rodgers A., Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, 2016; 387:957-67.
Bundy J.D., Li C., Stuchlik P., Bu X., Kelly T.N., Mills K.T., He H., Chen J., Whelton P.K., He J. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis. JAMA Cardiol, 2017; 2:775-81.
Aggarwal R., Chiu N., Wadhera R.K., Moran A.E., Raber I., Shen C., Yeh R.W., Kazi D.S. Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension, 2021; 78:1719-26.
Egan B.M., Li J., Sutherland S.E., Rakotz M.K., Wozniak G.D. Hypertension Control in the United States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Ageand Race-Ethnicity Groups. Hypertension, 2021; 78:578-87.
Townsend R.R, Mahfoud F., Kandzari D.E. et all. SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, 2017; 390:2160-70.
Kandzari D.E., Böhm M., Mahfoud F. Et all. SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, 2018; 391:2346-55.
Böhm M., Kario K., Kandzari D.E. et all. SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet, 2020; 395:1444-51.
Azizi M., Schmieder R.E., Mahfoud F. Et all. RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, 2018; 391:2335-45.
Azizi M., Sanghvi K., Saxena M. Et all. RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet, 2021; 397:2476-86.
Barbato E., Azizi M., Roland E. et all. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention, 2023; 18. DOI: 10.4244/EIJ-D-22-00723.
Anna M, Alexandru C, Marcel A, Nicolae C, Vitalie M, Artiom S, Maria C, Mihaela C, Alla F. The effect of renal denervation on the circadian blood pressure pattern in patients with resistant hypertension. Journal of Hypertension, 2022; Jun 1;40(Suppl 1):e245.
Moiseeva Anna. „Efectele denervării arterelor renale versus tratamentul farmacologic asupra valorilor tensionale și parametrilor funcției diastolice la pacienții cu hipertensiune arterială rezistentă la tratament.” Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 61.1 (2019): 180-184.
Downloads
Published
License
Copyright (c) 2023 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
